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Abstract
Background: Germline mutations affecting the exonuclease domains of POLE and 
POLD1 predispose to colorectal adenomas and carcinoma. Here, we aimed to screen 
the exonuclease domains to find the genetic causes of multiple colorectal polyps in 
unexplained cases.
Methods: Using a custom next‐generation sequencing panel, we sequenced the exo-
nuclease domains of POLE and POLD1 in 332 index patients diagnosed with multi-
ple colorectal polyps without germline alteration in colorectal polyposis predisposing 
genes.
Results: We identified two variants of unknown significance. One germline POLD1 
c.961G>A, p.(Gly321Ser) variant was found in two cases. The first patient was diag-
nosed with multiple polyps at age 35 and colorectal cancer (CRC) at age 37, with no 
known family history of CRC. The second patient was diagnosed with CRC at age 44 
and cumulatively developed multiple polyps; this patient had two sisters with endo-
metrial cancer who did not carry the variant. Furthermore, we identified a novel 
POLD1 c.955 T>G, p.(Cys319Gly) variant in a patient diagnosed with multiple 
colorectal adenomas at age 40. Co‐segregation analysis showed that one sister who 
cumulatively developed multiple adenomas from age 34, and another sister who de-
veloped CRC at age 38 did not carry the variant. We did not identify pathogenic vari-
ants in POLE and POLD1.
Conclusion: This study confirms the low frequency of causal variants in these genes 
in the predisposition for multiple colorectal polyps, and also establishes that these 
genes are a rare cause of the disease.
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1 |  INTRODUCTION
The heritable component of colorectal cancer (CRC) is ap-
proximately 35% (Lichtenstein et al., 2000), yet only up to 5% 
is associated with well‐characterized hereditary syndromes 
(Jasperson, Tuohy, Neklason, & Burt, 2010), which are caused 
by germline mutations in known high‐penetrance CRC genes 
(Al‐Tassan et al., 2002; Kinzler et al., 1991; Lynch & de la 
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Chapelle, 2003; Palles et al., 2013; Weren et al., 2015). A 
substantial proportion of CRC syndromes have been associ-
ated with malfunctioning DNA repair pathways (Al‐Tassan 
et al., 2002; Hendriks et al., 2006; Nicolaides et al., 1994; 
Peltomaki, 2001). Recently, an autosomal dominant CRC 
syndrome, caused by monoallelic germline mutations in the 
exonuclease domains of POLE (OMIM #174762) and POLD1 
(OMIM #174761), was identified. Palles et al. reported het-
erozygous germline variants in the exonuclease domains of 
the DNA polymerases POLE and POLD1. These variants 
predispose individuals, with a high penetrance, to multiple 
colorectal adenomas and early‐onset CRC. These mutations 
were found by whole‐genome sequencing and linkage analy-
sis in three large families that each possesses a dominant pat-
tern of CRC and multiple adenomas. Subsequent screening of 
3,805 CRC patients revealed that these variants are relatively 
rare in patients with a positive family history of adenomas or 
CRC: POLE p.(Leu424Val) was found 12 times and POLD1 
p.(Ser478Asn) only once. The tumors from the carriers were 
microsatellite stable and showed a hypermutated phenotype 
(Palles et al., 2013). Further studies have shown that POLE 
and POLD1 mutations predispose individuals to multiple ad-
enomas and early‐onset CRC (Bellido et al., 2016; Chubb et 
al., 2015; Elsayed et al., 2015; Esteban‐Jurado et al., 2017; 
Rohlin et al., 2016; Spier et al., 2015; Valle et al., 2014). The 
germline POLE p.(Leu424Val) mutation was demonstrated 
to also be associated with a Lynch syndrome‐like phenotype 
with microsatellite instable (MSI) tumors and somatic MSH6 
or MSH2/MSH6 protein loss in the tumors (Elsayed et al., 
2015). Additionally, POLE and POLD1 somatic mutations 
can give rise to a Lynch syndrome‐like phenotype and micro-
satellite instable colorectal cancer (Jansen et al., 2016). To 
discover the underlying genetic causes of multiple colorectal 
polyps and CRC in genetically unexplained cases, we aimed 
to screen the exonuclease domains of POLE and POLD1 in 
this group of patients. Generally, identification of new herita-
ble risk factors may play a role in increasing the understand-
ing of mechanisms underlying multiple polyp initiation and 
assist in the implementation of preventive strategies.
2 |  MATERIAL AND METHODS
2.1 | Samples
Ethical compliance; the study was approved by the local 
medical ethics committee of the Leiden University Medical 
Center (P01–019). A total of 332 index patients with multiple 
colorectal polyps were included in this study. All patients were 
originally referred to the Laboratory for Diagnostic Genome 
Analysis in Leiden for possible FAP or MAP syndrome; no 
potentially pathogenic germline variants were found in the 
entire genes APC (OMIM #611731) and MUTYH (OMIM 
#604933). More recently, the patients had tested negative 
for POLE NM_006231.2:c.1270C>G, p.(Leu424Val) and 
POLD1 NM_002691.3:c.1433G>A, p.(Ser478Asn) vari-
ants (Elsayed et al., 2015) and for NTHL1 (OMIM #602656) 
NM_002528.6:c.268C>T, p.(Gln90*). Clinical data were 
collected from the Netherlands Foundation for the Detection 
of Hereditary Tumors (NFDHT) and from clinical genet-
ics departments in the Netherlands; collected data included 
date of birth, gender, date of diagnosis with polyps, cumula-
tive number of polyps counted at colonoscopy or in excised 
bowel, location and histology of polyps, the presence of duo-
denal polyps, information on CRC, presence of polyps/CRC 
in first degree family members, date of last contact and status 
at last contact.
2.2 | Targeted next‐generation sequencing
Targeted next‐generation sequencing of leukocyte DNA was 
performed using a custom M13‐tailed sequencing panel on 
the Ion Torrent platform (Thermo Fisher, Waltham, MA). 
The exonuclease domains of POLE exons 9–14 and POLD1 
exons 8–12 were screened. Primers for overlapping ampli-
cons were designed using Primer3 (http://primer3.ut.ee/) and 
ordered from Integrated DNA Technologies (IDT Leuven, 
Belgium). Primer sequences are available upon request. 
Following the manufacturer's protocol ‐ briefly, PCR ampli-
cons were generated from 10 ng of leukocyte DNA using two 
primer pools. The PCR pools were subsequently combined 
and purified using AMPureXP beads. To add sample bar-
codes and Ion Torrent adapters, a second round of PCR was 
performed using M13 primers with A and P1 tails and sam-
ple barcodes. The PCR products were pooled, purified using 
AMPureXP beads and quantified using the Bioanalyzer High 
Sensitivity DNA kit (Agilent Technologies, Santa Clara, 
California). Size selection was performed, and the final con-
centration of the library was measured with a Bioanalyzer 
High Sensitivity DNA kit. Emulsion PCR was performed on 
an Ion One Touch 2 System (Thermo Fisher). The quality of 
the emulsion PCR was measured using the Qubit IonSphere 
Quality Control Kit, and libraries were sequenced using the 
Ion Personal Genome Machine (PGM).
2.3 | Data analysis
The sequence data were checked for quality using the qual-
ity control tool for high‐throughput sequence data, FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Subsequently, data were aligned to the human ge-
nome 19 (hg19, Genome Reference Consortium GRCh37) 
as a reference using the Burrows‐Wheeler Aligner (BWA, 
http://bio-bwa.sourceforge.net). Variant calling was per-
formed using VarScan software (http://varscan.sourceforge.
net/). Subsequently, variant annotation was performed with 
Annovar software (http://annovar.openbioinformatics.org). 
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Variants with a minor allele frequency (MAF) >1%, as re-
ported in dbSNP, ExAc or Go‐ESP, were also excluded. 
The Integrative Genomics Viewer (IGV, http://software.
broadinstitute.org/software/igv/) was used to visualize the 
read alignment and the presence of variants against the ref-
erence genome. Alamut software (Interactive Biosoft‐ware, 
Rouen, France), Align GVGD (http://agvgd.hci.utah.edu/
agvgd_input.php), PolyPhen‐2 (http://genetics.bwh.harvard.
edu/pph2/) and Combined Annotation Dependent Depletion 
(CADD, http://cadd.gs.washington.edu/snv) were used for 
variant interpretation.
2.4 | Validation and segregation analysis by 
Sanger sequencing
Sanger sequencing was performed to validate the POLD1 
NM_002691.3:c.961G>A, p.(Gly321Ser) and POLD1 
NM_002691.3:c.955 T>G, p.(Cys319Gly) variants de-
tected by the next‐generation sequencing panel, followed by 
co‐segregation analysis for available material from family 
members. Leukocyte DNA, in addition to both normal and 
tumor DNA, was used when available. Sanger sequencing 
was performed by Macrogen (Amsterdam, the Netherlands). 
Sequencing results were analyzed using Mutation Surveyor 
software (Sofgenetics, State College, PA).
3 |  RESULTS
A cohort of 332 Dutch patients with multiple colorectal pol-
yps, without known pathogenic germline mutations, were 
screened to identify mutations in the exonuclease domain of 
POLE and POLD1. The mean age at diagnosis of colorectal 
polyps was 55.48 years (range 13–82). Approximately 44.9% 
of the patients have adenomatous polyps, while 43.3% of the 
patients displayed a mixed phenotype, predominantly adeno-
mas with hyperplastic or serrated type. The majority of cases 
(56.6%) had a cumulative polyp count of 10 to 50. CRC was 
found in 126 patients (38%) at a mean age of diagnosis of 
53 years (range 21–80). Clinical characteristics of the index 
patients are summarized in Table 1. Using targeted next‐gen-
eration sequencing, we screened the exonuclease domain of 
POLE and POLD1. Two POLE NM_006231.2:c.1270C>G, 
p.(Leu424Val) mutation carriers that we previously re-
ported (Elsayed et al., 2015) were included as controls in 
this study. We detected the POLE c.1270C>G variant in 
the controls, but no additional POLE mutations were found. 
For POLD1, we identified two variants. A heterozygous 
germline POLD1 NM_002691.3:c.961G>A, p.(Gly321Ser) 
variant located in the exonuclease domain (EDM) was iden-
tified in patient P1. In silico analysis predicted that this vari-
ant is likely to affect the function of the protein. The amino 
acid is highly conserved across species, up to Baker's yeast, 
and highly conserved at the nucleotide level (PhyloP: 5.53). 
There are small physicochemical differences between gly-
cine and serine (Grantham distance: 56 [0–215]). Although 
the glycine and serine differ in polarity, charge and size, 
this change is considered a conservative amino acid sub-
stitution. This variant is predicted to be deleterious (SIFT 
score: 0.0), disease‐causing by Mutation Taster (p‐value: 1), 
possibly damaging by PolyPhen‐2 v2.2.2r398 (score of 0.88 
[sensitivity: 0.82; specificity: 0.94]), and likely to interfere 
with function by Align GVGD (class C55 [GV: 0.00 ‐ GD: 
55.27]). Furthermore, the Combined Annotation Dependent 
Depletion (CADD Phred, v1.3) is 29.7, predicting that this 
is may be pathogenic variant (Table 2). Patient P1 was di-
agnosed with multiple colorectal polyps at age 35 (>100 
polyps, mostly hyperplastic and some adenomas) and a mi-
crosatellite stable (MSS) CRC at age 37. In addition to the 
POLD1 variant, the patient is heterozygous for the patho-
genic NM_001128425.1:c.536A>G, p.(Tyr179Cys) vari-
ant in MUYTH. The patient has no known family history of 
CRC; furthermore, no analyzable tumor tissue is available 
for further study.
T A B L E  1  Clinical characteristics of the index patients included 
in this study (n = 332)









Adenoma + hyperplastic 103 (31.0%)
Adenomas + hyperplastic + serrated 32 (9.6%)
Adenoma + serrated 7 (2.1%)




Age at diagnosis with polyposis
>50 y 186 (56.0%)
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Another patient P2 was identified with the POLD1 
c.961G>A, p.(Gly321Ser) variant. The patient was diag-
nosed with CRC at age 44 and one adenomatous polyp with 
low‐grade dysplasia at age 47 and two serrated adenomas 
at age 54. She had two sisters with endometrial carcinoma 
(EC). Both sisters did not carry the variant (Figure 1a). 
The tumor from this patient is mismatch repair deficient 
(MMRD), with microsatellite instability (MSI‐H), nega-
tive MLH1/PMS2 immunohistochemistry and with MLH1 
promoter hypermethylation (OMIM #120436). No somatic 
mutations in KRAS (OMIM #190070) exon 2, codons 12/13 
and BRAF exon 15 (OMIM #164757) were found. Due to the 
highly degraded nature of the formalin‐fixed paraffin‐em-
bedded (FFPE) derived DNA, we were unable to determine 
the tumor mutation burden.
The second POLD1 NM_002691.3:c.955 T>G, p.(Cys-
319Gly) exonuclease domain variant was identified in a pa-
tient (P3) diagnosed with multiple colorectal polyps at ages 
40 and 51 (>100 adenomas). Co‐segregation was performed 
using available DNA from affected family members. One sis-
ter cumulatively developed multiple polyps from age 34; how-
ever, leukocyte DNA tested negative for the variant. Another 
sister, diagnosed with CRC at age 38, had both normal and 
tumor DNA available for further analysis. Using both DNA 
samples, this case was shown to be a noncarrier. No further 
DNA was available for two other affected family members 
(Figure 1b). This variant could affect the function of the pro-
tein, the affected amino acid is highly conserved and the af-
fected nucleotide is also moderately conserved (phylop: 2.87). 
With a large physicochemical difference between cysteine 
and glycine (Grantham distance: 159 [0–215]), the variant 
is predicted to most likely interfere with function of the pro-
tein by Align GVGD (class C65 [GV: 0.00–GD: 158.23]) and 
probably damaging by PolyPhen‐2 v2.2.2r398 (score of 1.00 
[sensitivity: 0.00; specificity: 1.00]). The CADD Phred v1.3 
score of 24.4, predicting that this is a pathogenic variant that 





alteration MAF rsID Mutation taster SIFT PolyPhen−2
Grantham 
distance Align GVGD Segregation CADD
Variant 
classification
P1, P2 c.961G>A p.Gly321Ser ExAC=0.0005 
Go‐ESP=0.0002 
TOPMED=0.0003
Rs41554817 Disease causing Deleterious Possibly damaging Predicted not to 
be deleterious
Likely to interfere 
with function
P1: Segregation not performed, 
unclear family history 
For P2: not segregate in tested 
family members
Predicted to be 
pathogenic
VUS
P3 c.955 T>G p.Cys319Gly N.A N.A Disease causing Deleterious Probably damaging Predicted to be 
deleterious
Highly likely to 
interfere with 
function
Not segregate in tested family 
members
Predicted to be 
pathogenic
VUS
Note. MAF: minor allele frequency; rsID: variant identifier in dbSNP, ExAc: exome aggregation consortium; Go‐ESP: exome sequencing project; TOPMED: 
trans‐omics in precision medicine; N3009.A: not available; CADD: Combined Annotation Dependent; VUS: variant of uncertain significance.
GenBank reference sequence: POLD1; NM_002691.3
FIGURE 1  Pedigrees of the families with germline POLD1 
variants. a, represents the family pedigree of the index patient P2 with 
POLD1 c.961G>A, p.(Gly321Ser). b, represents the family pedigree of 
index patient P3 with POLD1 c.955 T>G, p.(Cys319Gly). Filled symbol, 
cancer; symbol filled quarter, individual with colorectal polyps. [+], 
POLD1 variant carrier; [‐] noncarriers. The probands are indicated by an 
arrow. C, colorectal cancer; P, colorectal polyps; Ur, urothelial cell cancer; 
E, endometrial cancer; B, breast cancer; St, stomach cancer; Sk; skin 
cancer; d, deceased; number next to letter, ages at diagnosis or at death
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is furthermore supported by SIFT (score: 0) and Mutation 
Taster (p‐value: 1) (Table 2). In summary, this variant is a 
novel missense change that might be damaging to protein 
structure and function but did not show convincing co‐segre-
gation. No tumor material from the patient was available for 
further studies.
4 |  DISCUSSION
Pathogenic variants affecting the exonuclease domains of 
POLE and POLD1 are associated with polyposis and colo-
rectal cancer. Here, we screened the exonuclease domain of 
POLE and POLD1 to detect causative variants in 332 index 
patients with multiple colorectal polyps. We detected two 
missense heterozygous variants in POLD1. The POLD1 
c.961G>A, p.(Gly321Ser) variant was identified in two pa-
tients with multiple colorectal polyps and CRC. Gly321Ser is 
highly conserved and predicted to be damaging by in silico 
analysis tools. However, the available evidence is currently 
insufficient to evaluate the effect of this variant on the func-
tion of the protein; therefore, the variant is classified as a 
Variant of Unknown Significance (VUS). Co‐segregation 
analysis was not feasible in one of the families and not sup-
portive in the other family. In addition, the absence of avail-
able tumor tissue for functional analysis hampered further 
characterization of this VUS in P1. The tumor from patient 
P2 is MSI‐H with MLH1 promoter hypermethylation, there-
fore the mismatch repair deficiency phenotype is caused 
by somatic MLH1 promoter hypermethylation and not due 
to germline defects. While tumors from POLE and POLD1 
pathogenic variants carriers showed hypermutated phenotype 
(Elsayed et al., 2015; Palles et al., 2013), POLD1 tumors 
with exonuclease domain mutations at highly conserved 
motifs (Exo1, 11, 111) were not consistently hypermutant 
(Campbell et al., 2017). It has been shown that mutations in 
POLE and POLD1 do not always show a functional impact; 
therefore, determining the pathogenicity of mutations in 
these genes can be challenging (Campbell et al., 2017). The 
Gly321Ser variant is found in databases at a very low fre-
quency (rs41554817, ExAc = 0.0005, GO‐ESP = 0.0002 and 
TOPMED = 0.0003). Interestingly, patient P1 also carries a 
heterozygous MUTYH p.(Tyr179Cys) variant in addition to 
POLD1 c.961G>A, p.(Gly321Ser), possibly suggesting that 
both genes could act cooperatively and together confer an in-
creased CRC risk. The co‐occurrence of the MUTYH patho-
genic mutation with another mutation in MSH2 or MSH6 has 
been reported (Cohen, Tan, & Bisson, 2016; van Puijenbroek 
et al., 2007). Recently, a patient with the POLD1 c.961G>A, 
p.(Gly321Ser) variant was reported; this patient developed 
CRC at age 41. No segregation analysis could be performed 
for the family as no DNA was available (Jansen et al., 2016).
The exonuclease domain POLD1 c.955 T>G, p.(Cys-
319Gly) variant was identified in a patient who developed 
multiple colorectal polyps, with a family history of CRC 
and multiple polyps. The variant was only present in the 
patient but not in two affected siblings with CRC or multi-
ple polyps, suggesting a possible de novo POLD1 variant 
in patient P3. De novo mutations within POLE have been 
previously identified in some studies (Elsayed et al., 2015; 
Valle et al., 2014). While the in silico evidence suggests a 
pathogenic variant, the lack of co‐segregation in the fam-
ily is not supportive. No tumor material from this patient 
was available to analyze further. However, it is still un-
clear whether or not the variant impaired protein function. 
Functional assays are required for better evaluation of these 
variants. Notably, the POLD1 c.955 T>G, p.(Cys319Gly) 
variant was not observed in population databases (ExAc, 
GO‐ESP and TOPMED) and has not been reported in asso-
ciation with POLD1‐related disease. In the present study, 
we did not find pathogenic variants in POLE and POLD1. 
These genes have a low frequency in the predisposition for 
multiple polyps. It is worth mentioning that we previously 
evaluated the prevalence of the recurrent mutations POLE 





alteration MAF rsID Mutation taster SIFT PolyPhen−2
Grantham 
distance Align GVGD Segregation CADD
Variant 
classification
P1, P2 c.961G>A p.Gly321Ser ExAC=0.0005 
Go‐ESP=0.0002 
TOPMED=0.0003
Rs41554817 Disease causing Deleterious Possibly damaging Predicted not to 
be deleterious
Likely to interfere 
with function
P1: Segregation not performed, 
unclear family history 
For P2: not segregate in tested 
family members
Predicted to be 
pathogenic
VUS
P3 c.955 T>G p.Cys319Gly N.A N.A Disease causing Deleterious Probably damaging Predicted to be 
deleterious
Highly likely to 
interfere with 
function
Not segregate in tested family 
members
Predicted to be 
pathogenic
VUS
Note. MAF: minor allele frequency; rsID: variant identifier in dbSNP, ExAc: exome aggregation consortium; Go‐ESP: exome sequencing project; TOPMED: 
trans‐omics in precision medicine; N3009.A: not available; CADD: Combined Annotation Dependent; VUS: variant of uncertain significance.
GenBank reference sequence: POLD1; NM_002691.3
(Table 2. Continued)
6 of 7 |   ELSAYED Et AL.
c.1270C>G, p.(Leu424Val) and POLD1 c.1433G>A, 
p.(Ser478Asn) in a cohort of Dutch index patients with 
multiple polyps or familial CRC. Although we did not de-
tect POLD1 p.(Ser478Asn), three index patients with the 
POLE p.(Leu424Val) variant were detected (Elsayed et al., 
2015). Despite an enrichment in our cohort for inherited 
CRC and polyposis, the frequency (0.25%) is also compa-
rable to reported frequencies (Palles et al., 2013; Spier et 
al., 2015; Valle et al., 2014). These results confirm the low 
frequency of these genes as a rare cause of the disease.
Recently, both POLE and POLD1 mutations were iden-
tified outside of the exonuclease domains (Campbell et al., 
2017; Esteban‐Jurado et al., 2017; Spier et al., 2015), sug-
gesting other domains may be responsible for proofreading 
and should also be screened.
In conclusion, we identified no convincing pathogenic 
variants in exonuclease domains of POLE and POLD1 in the 
current study. We recommend that screenings of POLE and 
POLD1 should still be considered, although pathogenic vari-
ants in POLE and POLD1 probably occur at a low frequency 
in patients with multiple colorectal polyps. Multigene panels 
offer significant benefits over sequential single‐gene testing by 
reducing costs, time and increasing the sensitivity. Moreover, 
making feasible the analysis of multiple low‐frequency genes 
in the highly heterogenous syndromes. Indeed, including the 
two genes in multigene panels that are used to screen for pan‐
cancer mutations will allow to identify these rare mutations.
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